University of Pavia
Clinical Trials
123
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (89 trials with phase data)• Click on a phase to view related trials
Associations Between Radiographic Inclination of Premolars and Maxillary Expansion
- Conditions
- Maxillary Deficiency
- First Posted Date
- 2025-07-31
- Last Posted Date
- 2025-07-31
- Lead Sponsor
- University of Pavia
- Target Recruit Count
- 200
- Registration Number
- NCT07095374
- Locations
- 🇮🇹
Unit of Orthodontics and Pediatric Dentistry - Section of Dentistry - Department of Clinical, Surgical, Diagnostic and Pediatrics - University of Pavia, Pavia, Lombardy, Italy
Natural Bioactive Gel for Peri-Implantitis
- Conditions
- Peri-implantitisDental ImplantsNon-surgical Periodontal Therapy
- Interventions
- Drug: Sterify Gel (mucoadhesive bioactive gel)Procedure: Standard Non-Surgical Peri-Implantitis Therapy
- First Posted Date
- 2025-07-28
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- University of Pavia
- Target Recruit Count
- 20
- Registration Number
- NCT07088679
- Locations
- 🇮🇹
Unit of Orthodontics and Pediatric Dentistry - Section of Dentistry - Department of Clinical, Surgical, Diagnostic and Pediatrics - University of Pavia, Pavia, Lombardy, Italy
0.2% Chlorhexidine vs MicroRepair ABX in Gingivitis
- Conditions
- Gingivitis and Periodontal DiseasesDental PlaqueOral Hygiene
- Interventions
- Drug: MicroRepair ABX mouthwashDrug: Chlorhexidine 0.2% mouthwash
- First Posted Date
- 2025-07-28
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- University of Pavia
- Target Recruit Count
- 40
- Registration Number
- NCT07088666
- Locations
- 🇮🇹
Unit of Orthodontics and Pediatric Dentistry - Section of Dentistry - Department of Clinical, Surgical, Diagnostic and Pediatrics - University of Pavia, Pavia, Lombardy, Italy
Comparison of 0.12% Chlorhexidine and MicroRepair ABX Mouthwash in Gingivitis Management
- Conditions
- GingivitisDental PlaqueGingival Inflammation
- Interventions
- Drug: MicroRepair ABX mouthwashDrug: Chlorhexidine 0.12% mouthwash
- First Posted Date
- 2025-07-28
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- University of Pavia
- Target Recruit Count
- 40
- Registration Number
- NCT07088653
- Locations
- 🇮🇹
Unit of Orthodontics and Pediatric Dentistry - Section of Dentistry - Department of Clinical, Surgical, Diagnostic and Pediatrics - University of Pavia, Pavia, Lombardy, Italy
Mindfulness for Reducing Work-Related Stress
- Conditions
- Work-Related StressWell-beingInflammation StatusEmployees of University
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- University of Pavia
- Target Recruit Count
- 120
- Registration Number
- NCT07082491
- Locations
- 🇮🇹
University of Siena, Siena, Italy
- Prev
- 1
- 2
- 3
- 4
- 5
- 25
- Next
News
Solid Biosciences Receives FDA and Health Canada Approval for First-in-Class Gene Therapy Targeting Fatal Heart Rhythm Disorder
Solid Biosciences has received FDA IND and Health Canada CTA approval for SGT-501, a novel gene therapy designed to treat catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare genetic heart condition that can cause sudden death.
China's BNCT Cancer Treatment Breakthrough: Neuboron Medical Group Reports Success with First Domestic System
Neuboron Medical Group has established China's first accelerator-based Boron Neutron Capture Therapy (BNCT) center, making China the second country globally to offer this advanced cancer treatment technology.